미국 · 보도자료 · BJDX · 2026-10-06 10:30
패혈증 사망 위험 평가 임상 'SYMON-II' 세부 데이터 공개
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced baseline clinical characteristics from the SYMON-II clinical validation study, highlighting a substantial and diverse population of critically ill patients and clinically meaningful mortalit
